In contemporary medical practice, immune checkpoint blockade (ICB) has emerged as the foremost approach for cancer treatment.[1] This innovative therapeutic approach involves utilizing medications to disrupt the interaction between programmed cell death 1 (PD‐1) and its ligand (PD‐L1), thereby unleashing the immune system's ability to target and eliminate cancer cells.[2] However, despite the remarkable success of ICB in some cases, its efficacy is limited by the poor immune response exhibited by certain patients. Here, PDCD1 is linked to cancer.